GTEx Spleen 20-29 vs 30-39 Down (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GTEx Spleen 20-29 vs 30-39 Down.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GTEx Spleen 20-29 vs 30-39 Down.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GTEx Spleen 20-29 vs 30-39 Down.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GTEx Spleen 20-29 vs 30-39 Down.

Results found

Linked to

 

Label

Description

 

Gene

TSPEAR antisense RNA 1

Gene

long intergenic non-protein coding RNA 2454

Gene

TSIX transcript, XIST antisense RNA

Gene

keratin 87, pseudogene

Gene

long intergenic non-protein coding RNA 1638

Gene

MIR3681 host gene

Gene

long intergenic non-protein coding RNA 237

Gene

long intergenic non-protein coding RNA 2015

Gene

long intergenic non-protein coding RNA 1117

Gene

G protein pathway suppressor 2 pseudogene 1

  • Gene

    TSPEAR antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 2454


  • Gene

    TSIX transcript, XIST antisense RNA


  • Gene

    keratin 87, pseudogene


  • Gene

    long intergenic non-protein coding RNA 1638



  • Gene

    long intergenic non-protein coding RNA 237


  • Gene

    long intergenic non-protein coding RNA 2015


  • Gene

    long intergenic non-protein coding RNA 1117


  • Gene

    G protein pathway suppressor 2 pseudogene 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.